{"version":1,"type":"story","url":"https://digestai.news/story/novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55","json":"https://digestai.news/story/novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55.json","markdown":"https://digestai.news/story/novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55.md","slug":"novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55","headline":"Novo partners with Anthropic on Claude Science platform, shares up 3.55%","summary":"Novo Nordisk announced a strategic collaboration with Anthropic to use the Claude Science platform for accelerating pharmaceutical research and development. The partnership was disclosed alongside a 3.55% rise in Novo’s (NVO) share price, while rivals Eli Lilly (LLY) and Merck (MRK) also posted gains. CEO Mike Doustdar said artificial intelligence could \"compress the path from research to marketed product,\" and Anthropic co‑founder and CEO Dario Amodei said the deal is built to shorten research timelines and improve patient outcomes. Neither company revealed financial terms or specific therapeutic programs that will use the technology. Novo’s AI strategy already includes earlier work with OpenAI and an AI innovation centre with Amazon Web Services.\n\nThe European Medicines Agency’s advisory committee issued a positive recommendation for Frehemgo, Novo’s injectable hemophilia A therapy, covering adult and pediatric patients with or without inhibitors. Novo plans a limited European market launch in Q4 2026, followed by a broader EU rollout in early 2027. Clinical data from the FRONTIER trial showed lower annualized bleeding rates versus conventional clotting‑factor treatments, and the drug will be delivered in a prefilled, single‑use pen with flexible weekly to monthly dosing. To date, no AI‑discovered drug has achieved regulatory clearance, and Novo’s shares have fallen about 20% over the past year amid competition in the GLP‑1 weight‑loss market.","keyPoints":["Novo (NVO) shares rose 3.55% after announcing collaboration with Anthropic to use Claude Science for drug development.","EMA advisory committee gave a positive recommendation for Frehemgo, Novo’s hemophilia A therapy, slated for a Q4 2026 European launch.","Neither company disclosed financial terms; the deal follows prior AI partnerships with OpenAI and AWS, though no AI‑discovered drug has regulatory clearance yet."],"whyItMatters":"The partnership shows major pharma adopting generative AI to speed R&D, while the EMA endorsement of Frehemgo could boost Novo’s pipeline amid a share rebound.","category":{"slug":"business","name":"Business & Funding","url":"https://digestai.news/category/business"},"entities":{"companies":["Novo Nordisk","Anthropic","Eli Lilly","Merck","OpenAI","Amazon Web Services"],"models":["Claude Science"],"people":["Mike Doustdar","Dario Amodei"]},"firstPublishedAt":"2026-09-18T01:36:00Z","updatedAt":"2026-09-18T01:36:00Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"blockonomi.com","title":"Novo Nordisk (NVO) Stock Surges 4% on Anthropic AI Collaboration and European Drug Approval","url":"https://blockonomi.com/novo-nordisk-nvo-stock-surges-4-on-anthropic-ai-collaboration-and-european-drug-approval","publishedAt":"2026-09-18T01:36:00Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Novo partners with Anthropic on Claude Science platform, shares up 3.55%\", 18 September 2026, https://digestai.news/story/novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55","publisher":"Digest AI","title":"Novo partners with Anthropic on Claude Science platform, shares up 3.55%","datePublished":"2026-09-18T01:36:00Z","url":"https://digestai.news/story/novo-partners-with-anthropic-on-claude-science-platform-shares-up-3-55"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}